Rigrodsky & Long, P.A. Files Class Action Suit Against Proteon Therapeutics, Inc.

Friday, 06. December 2019 05:30

WILMINGTON, Del., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Proteon Therapeutics, Inc. (“Proteon”) (NASDAQ CM: PRTO) common stock in connection with the proposed merger of Proteon and ArTara Therapeutics, Inc. (“ArTara”) announced on September 23, 2019 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Proteon, its Board of Directors (the “Board”), and ArTara, is captioned Plumley v. Proteon Therapeutics, Inc., Case No. 1:19-cv-02143 (D. Del.).

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at info@rl-legal.com, or at http://rigrodskylong.com/contact-us/

On September 23, 2019, Proteon entered into an agreement and plan of merger (the “Merger Agreement”) with ArTara.  Pursuant to the terms of the Merger Agreement, ArTara stockholders will own approximately 90% of the combined company, while stockholders of Proteon will own approximately 10% (the “Proposed Transaction”).

Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a registration statement (the “Registration Statement”) filed with the United States Securities and Exchange Commission.  The Complaint alleges that the Registration Statement omits material information with respect to, among other things, the Company’s and ArTara’s financial projections and the analyses performed by Proteon’s financial advisor. The Complaint seeks injunctive and equitable relief and damages on behalf of holders of Proteon common stock. 

If you wish to serve as lead plaintiff, you must move the Court no later than February 3, 2020.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.


Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530

Primary Logo

Related Links: 
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.